Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Conditions

Multiple Myeloma · Relapsed/Refractory

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact: Study coordinator (Bing Xu) · xubingzhangjian@126.com

Study leads

Bing Xu
Principal Investigator
The First Aiffiliated hosptical of xiamen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Zhengzhou, China · Suzhou, China

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Duarte, United States

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Parkville, Australia

CAR-T in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma Refractory · Multiple Myeloma in Relapse

Abroad (travel likely)RecruitingPHASE2

Rawalpindi, Pakistan · Rawalpindi, Pakistan